Acer Therapeutics Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Schelling
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Gateway Center Newton MA United States of America 02458
- IPO Date
- Apr 14, 2004
- CIK
- 0001069308
- Website
- acertx.com
- Similar Companies
- Business
- Acer Therapeutics Inc. (Nasdaq:ACER), a wholly owned subsidiary of Zevra Therapeutics Inc., focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs; its primary commercial product is OLPRUVA (sodium phenylbutyrate), approved by the US FDA for treatment of urea cycle disorders including urea cycle disorders and Maple Syrup Urine Disease; investigational pipeline candidates include EDSIVO (celiprolol) for vascular Ehlers-Danlos syndrome in patients with confirmed type III collagen mutation, ACER-801 (osanetant) for induced vasomotor symptoms and other neuroendocrine disorders, and earlier-stage assets such as emetine hydrochloride and OPX-212. The company operates primarily in the United States, targeting patients with rare genetic and metabolic disorders through clinical trials, regulatory approvals, and commercial launches. Founded in 2013 and formerly headquartered in Newton, Massachusetts, Acer Therapeutics completed its acquisition by Zevra Therapeutics in November 2023 for approximately $91 million in stock, contingent value rights, and debt assumption, adding OLPRUVA as Zevra's first commercial asset and expanding its rare disease portfolio; this transaction followed FDA approval of OLPRUVA in 2022 and termination of a prior European license with Relief Therapeutics, with Zevra providing bridge financing to support ongoing commercialization efforts.
Russian LNG on the rise in EU – report
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra
ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ACER's Stock Down on Failure of Phase II Study, Cash Updates
7 Penny Stocks With Strong Insider Buying Signals
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?
Acer Therapeutics Inc. (ACER) Upgraded to Strong Buy: What Does It Mean for the Stock?
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?
Acer Therapeutics to Participate in August and September 2022 Investor Conferences